SAB Biotherapeutics (SABS) Projected to Post Quarterly Earnings on Monday

SAB Biotherapeutics (NASDAQ:SABS) will likely be announcing its Q1 2025 earnings results before the market opens on Monday, May 19th. Analysts expect the company to announce earnings of ($1.00) per share and revenue of $0.13 million for the quarter.

SAB Biotherapeutics (NASDAQ:SABS) last issued its earnings results on Friday, May 9th. The company reported ($0.56) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.00) by $0.44. SAB Biotherapeutics had a negative return on equity of 94.37% and a negative net margin of 1,450.14%. On average, analysts expect SAB Biotherapeutics to post $-4 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

SAB Biotherapeutics Price Performance

Shares of NASDAQ:SABS opened at $1.85 on Friday. The company has a quick ratio of 3.69, a current ratio of 3.69 and a debt-to-equity ratio of 0.09. The stock has a market capitalization of $17.19 million, a PE ratio of -0.50 and a beta of 0.47. The firm’s 50 day moving average price is $1.52 and its 200-day moving average price is $2.51. SAB Biotherapeutics has a twelve month low of $1.00 and a twelve month high of $5.01.

Wall Street Analysts Forecast Growth

A number of brokerages have issued reports on SABS. HC Wainwright assumed coverage on shares of SAB Biotherapeutics in a report on Wednesday. They set a “buy” rating and a $10.00 price objective for the company. Chardan Capital restated a “buy” rating and issued a $20.00 price target on shares of SAB Biotherapeutics in a research report on Thursday. Five research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average price target of $12.20.

About SAB Biotherapeutics

SAB Biotherapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at infectious diseases and immune and autoimmune disorders, including infectious diseases, influenza, CDI, type 1 diabetes, organ transplantation, and oncology, as well as immunology, gastroenterology, and respiratory diseases.